TXNIP and acute myeloid leukemia: In the following assessment of the genetic mutation of PRGs in depth, only CASP3 (1%), NLRC4 (1%), NLRP1 (1%), NLRP2 (1%), NLRP3 (1%), TFAM (1%), and TXNIP (1%) showed the genetic mutation in AML patients (Figure 1C).